Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma
Joë-Marc Chauvin, Mignane Ka, Ornella Pagliano, et al.
Clinical Cancer Research (2020) Vol. 26, Iss. 20, pp. 5520-5533
Open Access | Times Cited: 115

Showing 1-25 of 115 citing articles:

Natural killer cells in cancer biology and therapy
Song‐Yang Wu, Tong‐Ming Fu, Yi‐Zhou Jiang, et al.
Molecular Cancer (2020) Vol. 19, Iss. 1
Open Access | Times Cited: 627
TIGIT in cancer immunotherapy
Joë-Marc Chauvin, Hassane M. Zarour
Journal for ImmunoTherapy of Cancer (2020) Vol. 8, Iss. 2, pp. e000957-e000957
Open Access | Times Cited: 590
Natural killer cells in antitumour adoptive cell immunotherapy
Tamara Laskowski, Alexander Biederstädt, Katayoun Rezvani
Nature reviews. Cancer (2022) Vol. 22, Iss. 10, pp. 557-575
Open Access | Times Cited: 482
TIGIT, the Next Step Towards Successful Combination Immune Checkpoint Therapy in Cancer
Zhouhong Ge, Maikel P. Peppelenbosch, Dave Sprengers, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 162
Targeting the PI3K/AKT/mTOR Pathway in Hormone-Positive Breast Cancer
Sara Nunnery, Ingrid A. Mayer
Drugs (2020) Vol. 80, Iss. 16, pp. 1685-1697
Open Access | Times Cited: 141
Harnessing natural killer cells for cancer immunotherapy: dispatching the first responders
Nicholas A. Maskalenko, Dmitry Zhigarev, Kerry S. Campbell
Nature Reviews Drug Discovery (2022) Vol. 21, Iss. 8, pp. 559-577
Open Access | Times Cited: 140
Emerging concepts in PD-1 checkpoint biology
Kristen E. Pauken, James A. Torchia, Apoorvi Chaudhri, et al.
Seminars in Immunology (2021) Vol. 52, pp. 101480-101480
Open Access | Times Cited: 134
TIGIT-CD226-PVR axis: advancing immune checkpoint blockade for cancer immunotherapy
Eugene Y. Chiang, Ira Mellman
Journal for ImmunoTherapy of Cancer (2022) Vol. 10, Iss. 4, pp. e004711-e004711
Open Access | Times Cited: 127
Exploiting innate immunity for cancer immunotherapy
Ming Yi, Tianye Li, Mengke Niu, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 84
Innovative breakthroughs facilitated by single-cell multi-omics: manipulating natural killer cell functionality correlates with a novel subcategory of melanoma cells
Zhijie Zhao, Yantao Ding, Lisa Jia Tran, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 72
T cell-derived interleukin-22 drives the expression of CD155 by cancer cells to suppress NK cell function and promote metastasis
Daria Briukhovetska, Javier Suárez-Gosálvez, Cornelia Voigt, et al.
Immunity (2023) Vol. 56, Iss. 1, pp. 143-161.e11
Open Access | Times Cited: 50
Novel strategies for cancer immunotherapy: counter-immunoediting therapy
Shaochuan Liu, Qian Sun, Xiubao Ren
Journal of Hematology & Oncology (2023) Vol. 16, Iss. 1
Open Access | Times Cited: 49
TIGIT, a novel immune checkpoint therapy for melanoma
Wei Tang, Jun Chen, Tianlong Ji, et al.
Cell Death and Disease (2023) Vol. 14, Iss. 7
Open Access | Times Cited: 48
Beyond CTLA-4 and PD-1 Inhibition: Novel Immune Checkpoint Molecules for Melanoma Treatment
Dimitrios C. Ziogas, Charalampos Theocharopoulos, Panagiotis-Petros Lialios, et al.
Cancers (2023) Vol. 15, Iss. 10, pp. 2718-2718
Open Access | Times Cited: 43
Targeting TIGIT for cancer immunotherapy: recent advances and future directions
Peng Zhang, Xinyuan Liu, Zhuoyu Gu, et al.
Biomarker Research (2024) Vol. 12, Iss. 1
Open Access | Times Cited: 32
Development of pharmacological immunoregulatory anti-cancer therapeutics: current mechanistic studies and clinical opportunities
Nanhao Yin, Xintong Li, Xuanwei Zhang, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 20
TIGIT/CD226 Axis Regulates Anti-Tumor Immunity
Jinah Yeo, Minkyung Ko, Dong-Hee Lee, et al.
Pharmaceuticals (2021) Vol. 14, Iss. 3, pp. 200-200
Open Access | Times Cited: 104
Interleukin-15 and cancer: some solved and many unsolved questions
Piera Filomena Fiore, Sabina Di Matteo, Nicola Tumino, et al.
Journal for ImmunoTherapy of Cancer (2020) Vol. 8, Iss. 2, pp. e001428-e001428
Open Access | Times Cited: 73
A Phase 1a/b Open-Label, Dose-Escalation Study of Etigilimab Alone or in Combination with Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumors
Niharika B. Mettu, Susanna V. Ulahannan, Johanna C. Bendell, et al.
Clinical Cancer Research (2021) Vol. 28, Iss. 5, pp. 882-892
Open Access | Times Cited: 58
NK Cells in Cancer: Mechanisms of Dysfunction and Therapeutic Potential
Federica Portale, Diletta Di Mitri
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 11, pp. 9521-9521
Open Access | Times Cited: 30
Understanding NK cell biology for harnessing NK cell therapies: targeting cancer and beyond
Eunju Shin, Seong Ho Bak, Tae‐Ho Park, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 30
synNotch-programmed iPSC-derived NK cells usurp TIGIT and CD73 activities for glioblastoma therapy
Kyle B. Lupo, Xue Yao, Shambhavi Borde, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 14
Inhibitory Receptors and Immune Checkpoints Regulating Natural Killer Cell Responses to Cancer
Irina Buckle, Camille Guillerey
Cancers (2021) Vol. 13, Iss. 17, pp. 4263-4263
Open Access | Times Cited: 53
An engineered oncolytic vaccinia virus encoding a single-chain variable fragment against TIGIT induces effective antitumor immunity and synergizes with PD-1 or LAG-3 blockade
Shuguang Zuo, Min Wei, Tiancheng Xu, et al.
Journal for ImmunoTherapy of Cancer (2021) Vol. 9, Iss. 12, pp. e002843-e002843
Open Access | Times Cited: 53
Recent Advancements in the Mechanisms Underlying Resistance to PD-1/PD-L1 Blockade Immunotherapy
Yu Yuan, Abdalla Adam, Chen Zhao, et al.
Cancers (2021) Vol. 13, Iss. 4, pp. 663-663
Open Access | Times Cited: 50
Page 1 - Next Page

Scroll to top